Electra Therapeutics (NASDAQ:ETRA) Upgraded to “Hold” at Zacks Research

Electra Therapeutics (NASDAQ:ETRA) was upgraded by research analysts at Zacks Research to a “hold” rating in a note issued to investors on Wednesday, Zacks reports.

Other analysts have also issued research reports about the company. Jefferies Financial Group assumed coverage on Electra Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $32.00 price target for the company. TD Cowen started coverage on shares of Electra Therapeutics in a research report on Tuesday. They set a “buy” rating on the stock. Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. Evercore assumed coverage on shares of Electra Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Electra Therapeutics in a research report on Tuesday. They issued an “overweight” rating for the company. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $34.00.

Electra Therapeutics Trading Down 2.1%

ETRA opened at $8.75 on Wednesday. Electra Therapeutics has a 52-week low of $8.50 and a 52-week high of $15.50.

Insider Activity at Electra Therapeutics

In other news, Director Orbimed Advisors Llc bought 1,333,333 shares of the firm’s stock in a transaction dated Monday, September 21st. The stock was purchased at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the transaction, the director owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. The trade was a 35.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carl L. Gordon bought 1,333,333 shares of the firm’s stock in a transaction dated Monday, September 21st. The stock was purchased at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the transaction, the director directly owned 5,126,891 shares in the company, valued at approximately $76,903,365. This represents a 35.15% increase in their position. The SEC filing for this purchase provides additional information.

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.